1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Kailera/Hengrui’s GLP-1/GIP Agonist Candidate Could Have Better Efficacy

 
• By Alaric DeArment

The companies announced Phase II data showing a 22.8% mean weight reduction, but with no plateau, suggesting potentially further weight loss as time goes on.

Magnifying glass over GLP-1 on blackboard
• Source: Shutterstock

Kailera Therapeutics and Hengrui Pharma are stepping into the obesity ring with strong Phase II data for their dual agonist of GLP-1 and GIP for overweight and obesity HRS9531, also known as KAI-9531, which Hengrui is moving through Phase III development in China and which they plan to develop in a global Phase III program as well. The companies see the potential for potentially greater weight loss given the lack of a plateau at 36 weeks.

Key Takeaways
  • Kailera/Hengrui announced topline results from a Phase II study of their dual GLP-1/GIP receptor agonist HRS9531 showing 22.8% mean weight loss from baseline at 36 weeks.

Boston-based Kailera and Hengrui, based in Lianyungang, China, announced 13 January topline data from the 8mg dose of Hengrui’s Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

More from Scrip

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.